search
diabetes
Trends
- 1Doctors warn of heat risks for GLP-1 drug users▼Amid heat wave, doctors warn of health risks for people taking GLP-1 drugs
As a heat wave grips much of the United States, doctors are warning that people taking GLP-1 medications, such as Ozempic and Wegovy, may face heightened health risks. These drugs can contribute to dehydration, which raises the danger of heat exhaustion and other heat-related illness. Health professionals are advising patients on GLP-1 therapies to drink plenty of fluids, limit strenuous outdoor activity, and watch for warning signs like dizziness and nausea during extreme temperatures.
- 2Pancreatic Cells One Genetic Tweak From Diabetes Treatment●Some Pancreatic Cells Are Just One Genetic Tweak Away From Treating Diabetes https:// fed.brid.gy/r/https://www.wire d.c
New reporting from Wired describes research showing that some pancreatic cells may need only a single genetic change to become capable of producing insulin, raising hopes for a new diabetes treatment. The finding suggests a potential regenerative pathway for restoring insulin production in patients, and it is drawing attention in science and health communities.
- 3India proposes junk food ban near schools●India tightens school junk food rules amid obesity rise India proposes banning junk food sales in school canteens and wi
India has proposed banning junk food sales in school canteens and within 50 meters of schools, a move aimed at curbing rising obesity and diabetes rates among children. The proposal, reported by Reuters, marks a tightening of rules around food sold in and around educational institutions, and is drawing attention to concerns over children's health and diet.
- 4Eli Lilly CEO Pins Growth Hopes On Retatrutide▼Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’
Eli Lilly's chief executive said the company's future has 'never been brighter' as it positions retatrutide, its experimental weight-loss and diabetes drug, as the next major growth driver. The statement follows strong investor interest in Lilly's obesity pipeline, which already includes the blockbuster tirzepatide. Retatrutide is in late-stage trials and is viewed as a potential rival to next-generation obesity treatments. Markets are watching closely as competition in the weight-loss drug market intensifies with Novo Nordisk and others.
- 5Pancreatic Cells One Genetic Tweak From Treating Diabetes●Some Pancreatic Cells Are Just One Genetic Tweak Away From Treating Diabetes https://www.wired.com/story/pancreatic-cell
New research reported by Wired suggests some pancreatic cells could be converted into insulin-producing cells through a single genetic modification, offering a potential new avenue for treating diabetes. The findings point to reprogramming existing cells rather than replacing them, a possibility researchers say could one day change how the disease is managed.
- 6Study links GLP-1 drugs in children to nutritional deficiencies●Interactive: Study links GLP-1 use in children to nutritional deficiencies
A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.
- 7Heart and Kidney Problems Rise Over Time in Type 2 Diabetes●Heart and Kidney Problems in Type 2 Diabetes Patients Increase with Time
Type 2 diabetes patients face a growing burden of heart and kidney complications the longer they live with the disease, according to a report covered by Inside Precision Medicine. The findings highlight how cardiovascular and renal risks accumulate with disease duration, underscoring the importance of early monitoring and treatment to protect the heart and kidneys in people with diabetes.